To analyze the constituents of essential oil from Chinese eaglewood [resinous wood of Aquilaria sinensis （Lour.） Gilg] and its anti-methicillin-resistant Staphylococcus aureus （MRSA） activity. The essential oil wa...To analyze the constituents of essential oil from Chinese eaglewood [resinous wood of Aquilaria sinensis （Lour.） Gilg] and its anti-methicillin-resistant Staphylococcus aureus （MRSA） activity. The essential oil was extracted by water-steam distillation and analyzed by GC/MS method. The relative contents of the compounds were determined by normalization. The compounds were characterized by NIST05 and WILEY275L database matching and comparison of their MS spectra with those of literature data. Antibacterial activity of the oil was assayed by the filter paper disc agar diffusion method. The oil showed significant antibacterial activity against MRSA. Sixty-six chromatographic peaks were detected, among them thirty compounds comprising 59.80% of the total essential oil were characterized. Twenty-six compounds comprising 54.26% of the oil were identified as sesquiterpenes. β-Agarofuran （8.96%）, kusunol （7.82%）, （-）-jinkoh-eremol （5.04%）, agarospirol （4.53%）, baimuxifuranic acid （4.09%） were the major sesquiterpenes. Four nor-sesquiterpenes and some other sesquiterpenes, such as 10-epi-γ-eudesmol, α-agarofuran, epi-ligulyl oxide, etc. were detected in Chinese eaglewood oil for the first time. This is the first report about anti-MRSA activity of Chinese eaglewood oil from A. sinensis.展开更多
The emergence and rapid spread of multidrug-resistant gram-positive bacteria has become a vital and serious medical problem. A literature search was conducted in Pub Med, EMBASE, and Elsevier databases to identify rel...The emergence and rapid spread of multidrug-resistant gram-positive bacteria has become a vital and serious medical problem. A literature search was conducted in Pub Med, EMBASE, and Elsevier databases to identify relevant publications. To calculate the risk ratios（RRs） with 95% confidential intervals（CIs）, a fixed- or random-effects model was applied based on the heterogeneity across studies. Five studies containing seven RCTs were included in this meta-analysis. Regarding c SSTIs, HAP, SAB, there was no statistically significant difference in the rate of clinical cure between telavancin and vancomycin or standard therapy in intention-to-treat population（ITT）（RR 1.01, 95% CI 0.97–1.05, P = 0.72; FEM） and clinically evaluable population（CE）（RR 1.01, 95% CI 0.98–1.04, P = 0.41; FEM）. However, telavancin was more effective than vancomycin or standard therapy in MRSA eradication rate（RR 1.08, 95% CI 1.02–1.14, P = 0.009; FEM）. Regarding the safety profile, no statistically significant differences were found in all-cause mortality（9.0% vs. 8.4%; RR 1.07, 95% CI 0.88–1.31, P = 0.49; FEM） and overall adverse events（77.0% vs. 72.3%; RR 1.08, 95% CI 0.98–1.20, P = 0.12; FEM） between telavancin and vancomycin or standard therapy. Pooled data from c SSTIs, HAP and SAB studies on telavancin indicated higher rates of adverse-event related withdrawals（7.7% vs. 5.4%; RR 1.43, 95% CI 1.12–1.83, P = 0.05; FEM） and creatinine elevation（10.0% vs. 5.1%; RR 1.95, 95% CI 1.53–2.48, P0.00001; FEM） than vancomycin or standard therapy. Telavancin and vancomycin or standard therapy are equally effective for the treatment of c SSTIs, HAP and SAB, and telavancin might be an option for the treatment of difficult-to-treat serious infections caused by MRSA. However, telavancin is associated a higher incidence of creatinine elevation and adverse-event related withdrawals.展开更多
基金Foundation items:National Basic Research Program of China(Grant No.2007CB 116306)Science and Technology Foundation of Chinese Academy of Tropical Agricultural Sciences(Grant No.RKY0726)National Nonproft Institute Research Grant of CATAS-ITBB(Grant No.ITBBZDO743).
文摘To analyze the constituents of essential oil from Chinese eaglewood [resinous wood of Aquilaria sinensis （Lour.） Gilg] and its anti-methicillin-resistant Staphylococcus aureus （MRSA） activity. The essential oil was extracted by water-steam distillation and analyzed by GC/MS method. The relative contents of the compounds were determined by normalization. The compounds were characterized by NIST05 and WILEY275L database matching and comparison of their MS spectra with those of literature data. Antibacterial activity of the oil was assayed by the filter paper disc agar diffusion method. The oil showed significant antibacterial activity against MRSA. Sixty-six chromatographic peaks were detected, among them thirty compounds comprising 59.80% of the total essential oil were characterized. Twenty-six compounds comprising 54.26% of the oil were identified as sesquiterpenes. β-Agarofuran （8.96%）, kusunol （7.82%）, （-）-jinkoh-eremol （5.04%）, agarospirol （4.53%）, baimuxifuranic acid （4.09%） were the major sesquiterpenes. Four nor-sesquiterpenes and some other sesquiterpenes, such as 10-epi-γ-eudesmol, α-agarofuran, epi-ligulyl oxide, etc. were detected in Chinese eaglewood oil for the first time. This is the first report about anti-MRSA activity of Chinese eaglewood oil from A. sinensis.
文摘The emergence and rapid spread of multidrug-resistant gram-positive bacteria has become a vital and serious medical problem. A literature search was conducted in Pub Med, EMBASE, and Elsevier databases to identify relevant publications. To calculate the risk ratios（RRs） with 95% confidential intervals（CIs）, a fixed- or random-effects model was applied based on the heterogeneity across studies. Five studies containing seven RCTs were included in this meta-analysis. Regarding c SSTIs, HAP, SAB, there was no statistically significant difference in the rate of clinical cure between telavancin and vancomycin or standard therapy in intention-to-treat population（ITT）（RR 1.01, 95% CI 0.97–1.05, P = 0.72; FEM） and clinically evaluable population（CE）（RR 1.01, 95% CI 0.98–1.04, P = 0.41; FEM）. However, telavancin was more effective than vancomycin or standard therapy in MRSA eradication rate（RR 1.08, 95% CI 1.02–1.14, P = 0.009; FEM）. Regarding the safety profile, no statistically significant differences were found in all-cause mortality（9.0% vs. 8.4%; RR 1.07, 95% CI 0.88–1.31, P = 0.49; FEM） and overall adverse events（77.0% vs. 72.3%; RR 1.08, 95% CI 0.98–1.20, P = 0.12; FEM） between telavancin and vancomycin or standard therapy. Pooled data from c SSTIs, HAP and SAB studies on telavancin indicated higher rates of adverse-event related withdrawals（7.7% vs. 5.4%; RR 1.43, 95% CI 1.12–1.83, P = 0.05; FEM） and creatinine elevation（10.0% vs. 5.1%; RR 1.95, 95% CI 1.53–2.48, P0.00001; FEM） than vancomycin or standard therapy. Telavancin and vancomycin or standard therapy are equally effective for the treatment of c SSTIs, HAP and SAB, and telavancin might be an option for the treatment of difficult-to-treat serious infections caused by MRSA. However, telavancin is associated a higher incidence of creatinine elevation and adverse-event related withdrawals.
